CEO Executive AssistantCompetitive intelligence and market research are foundational to sound strategic decision-making in the pharmaceutical industry. Understanding how competitor pipelines are progressing, how physicians are responding to competing products, how payer coverage decisions are evolving, and how key market dynamics are shifting is essential for making good decisions about pipeline prioritization, commercial strategy, and business development.
Yet competitive intelligence is also a function that can consume executive time in highly inefficient ways. When CEOs are reviewing competitive analyses themselves, attending multiple CI briefings per week, or directing individual research requests, they are doing work that a well-built intelligence system should handle. This article describes how pharma CEOs can build a delegation system for competitive intelligence and market research that delivers strategic insight without requiring active CEO management of the function.
Why a Delegation System Is Needed
Many pharma companies lack a coherent competitive intelligence function. Instead, CI responsibilities are distributed informally across strategy, commercial, R&D, and business development. Each function monitors the competitive landscape relevant to its work without systematic integration across the organization. This creates duplication of effort, gaps in coverage, and an absence of the cross-functional synthesis that produces the most strategically valuable insights.
When CI is fragmented, the CEO is often the de facto integrator: receiving pieces of competitive information from multiple sources and personally assembling them into a strategic picture. This is an inefficient and unsustainable use of executive bandwidth.
Building a proper CI delegation system means centralizing intelligence production and delivery so that the CEO receives integrated, synthesized competitive insights rather than raw data from multiple disconnected sources.
The Architecture of an Effective CI Delegation System
Central CI function or team
The foundation of an effective CI delegation system is a dedicated intelligence function, even if it is small. A team of two to four CI professionals, led by a Director of Competitive Intelligence, can manage the processes that keep the competitive landscape continuously monitored and synthesized for leadership consumption.
This team is responsible for: maintaining a competitive intelligence database covering key competitors, pipeline assets, clinical trial status, commercial performance, and regulatory activities; producing regular CI reports for functional and executive audiences; managing primary research programs (including physician advisory boards, market research, and competitive intelligence surveys); coordinating with external CI vendors and data providers; and ensuring that competitive insights are connected to strategic planning and business decision-making processes.
Functional CI owners
In addition to the central CI team, each major function should have a designated CI focal point who is responsible for integrating competitive information relevant to their function and ensuring that the central CI team is informed of function-specific intelligence needs and findings.
In R&D, the CI focal point monitors competitor pipelines, clinical trial designs, and scientific publications. In commercial, the focal point tracks competitor commercial strategies, market share, and promotional activities. In regulatory, the focal point tracks competitor regulatory submissions, approvals, and FDA engagement. In business development, the focal point tracks competitor M&A activity, licensing deals, and partnership strategies.
External data and analytics providers
Pharma CI functions typically rely on a combination of publicly available information and proprietary commercial databases. Key data providers include IQVIA, Evaluate Pharma, Citeline, and others. Managing these vendor relationships and ensuring the organization is getting maximum value from data investments is a function that belongs to the CI team, not the CEO.
What the CEO Should Receive From the CI System
The CEO’s role in the delegation system is to consume intelligence outputs, not to manage the intelligence production process. The specific outputs the CEO should receive are:
A weekly competitive intelligence digest (2 to 3 pages) covering the most important competitive developments of the prior week across the company’s key therapeutic areas and strategic topics. This digest is produced by the CI function and delivered to the CEO and executive team.
A monthly competitive landscape review (30 to 45 minutes with the CI director or strategy lead) that provides a deeper analysis of competitive trends, pipeline movements, and market dynamics. This review should connect competitive insights to the implications for the company’s strategy.
Rapid-response intelligence briefings when significant competitive events occur: competitor regulatory approvals, major clinical trial results, significant M&A activity, or unexpected competitive moves that warrant immediate strategic discussion.
Annual competitive strategy review, which is part of the broader strategic planning process and includes a comprehensive competitive landscape assessment informing the company’s three to five year strategic choices.
Integrating CI Into Business Decision-Making
The most common failure mode for pharma CI systems is that intelligence is produced but not effectively connected to decision-making. The CEO should ensure that the CI function is integrated into the company’s key decision forums, not operating as a separate intelligence operation with limited connection to the business.
Practical integration mechanisms include: requiring competitive landscape updates as standing agenda items in pipeline review and portfolio prioritization meetings; including CI function representation in commercial brand planning processes; ensuring that BD and licensing decisions are informed by up-to-date competitive analysis; and including competitive position assessments in strategic planning submissions from each business unit.
The CI director should have a standing relationship with the strategy function and the CEO’s office to ensure that intelligence needs arising from executive discussions are captured and addressed by the CI team.
Delegating Primary Market Research
Market research (physician surveys, patient research, payer research, and advisory boards) is closely related to competitive intelligence but serves somewhat different purposes. Primary market research is often used to understand physician attitudes toward a product or therapy area, patient experience with disease and treatment, or payer coverage criteria and formulary decision-making.
The CEO should ensure that market research is coordinated across functions to avoid duplication and to ensure consistent methodology and interpretation. A common problem is that commercial, medical affairs, and R&D all commission market research independently, resulting in fragmented and sometimes contradictory findings.
The solution is to establish a market research function or coordinator who maintains an inventory of active and planned research studies, ensures methodological consistency, and provides cross-functional synthesis of market research findings. This function typically sits within commercial or the central CI team.
The CEO should receive a quarterly summary of key market research findings and their strategic implications, not raw research output.
Managing Competitive Intelligence Confidentiality and Ethics
Pharmaceutical competitive intelligence must operate within clear ethical and legal boundaries. Trade secret misappropriation, inappropriate use of confidential information, and competitive intelligence gathering that involves deceptive practices create legal liability and reputational risk.
The CEO should ensure that the CI function operates with a clear ethics policy governing how intelligence is gathered and used, and that all team members are trained on appropriate CI practices. This governance responsibility belongs to the CI function in coordination with legal and compliance, not to the CEO personally. The CEO should be informed of any CI practices concerns through the legal and compliance escalation channels.
Linking CI to Portfolio Strategy
One of the most valuable uses of competitive intelligence for pharma CEOs is informing portfolio prioritization decisions. Understanding how the competitive landscape in a given therapeutic area is likely to evolve over the next five years should inform decisions about which pipeline assets to advance, which therapeutic areas to invest in, and which business development opportunities to pursue.
The CEO should ensure that portfolio review processes systematically incorporate competitive landscape analysis rather than treating competitive context as background information. This means requiring the CI function to contribute to portfolio review documentation and ensuring that pipeline prioritization discussions are informed by a clear picture of competitive positioning.
For broader guidance on how pharma CEOs manage pipeline and portfolio decisions, the R&D delegation framework provides relevant context. For the business development dimension of competitive intelligence, the digital health strategy guide covers related territory.
Building the CI Talent and Technology Infrastructure
The quality of competitive intelligence output depends on the quality of the people and technology supporting the function. Pharma CEOs should ensure appropriate investment in:
CI talent: experienced intelligence analysts who understand drug development, clinical data, regulatory affairs, and commercial dynamics. The best CI professionals combine scientific literacy with strategic analysis skills and can translate complex technical information into clear strategic implications.
Technology infrastructure: modern CI platforms that aggregate and organize competitive information efficiently, reducing the time team members spend on data gathering and increasing the time available for analysis and synthesis.
External expert networks: access to physician opinion leaders, healthcare economists, and regulatory experts who can provide qualitative context to complement quantitative data sources.
Practical Steps for CEOs
Pharma CEOs who want to improve their competitive intelligence delegation system can take the following practical steps:
Audit how CI is currently produced and consumed: identify the functions producing CI, the quality and consistency of what is delivered, and the degree to which CI is actually informing decisions.
Assess whether a central CI function exists and whether it has the capability, authority, and budget to serve as the organization’s primary intelligence source.
Define the CEO’s specific CI requirements: what does the CEO need to know, at what frequency, and in what format to make better strategic decisions?
Ensure CI is integrated into key decision forums: pipeline reviews, portfolio prioritization, commercial planning, and BD evaluation should all systematically incorporate CI input.
Invest in CI infrastructure where gaps exist: talent, technology, and external data partnerships.
Conclusion
A well-built competitive intelligence delegation system allows pharma CEOs to maintain strategic situational awareness without managing the mechanics of intelligence gathering and analysis. By investing in the right CI infrastructure, centralizing production of integrated intelligence outputs, and defining a clear governance model for CI consumption, pharma CEOs can build an organization that is consistently well-informed about the competitive landscape and capable of making decisions that account for competitive reality. The result is better strategy and better resource allocation, with the CEO’s competitive intelligence needs met efficiently and consistently.
Related Reading
For further context, explore Delegation System for Automotive CEO: Compliance Team and Delegation System for Automotive CEO: Engineering Teams.